Business Context and Reporting Period
Company: Akari Therapeutics Plc (AKTX)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Akari is an oncology company developing next-generation antibody-drug conjugates (ADCs) utilizing a proprietary payload platform (PH1) that targets RNA splicing. The company has suspended development of legacy assets (nomacopan, PAS-nomacopan, PHP-303) to focus resources on its lead candidate, AKTX-101 (Trop-2 targeting), and AKTX-102 (CEACAM5 targeting). As of December 31, 2025, the company has no commercial products and has not generated product revenue.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(17.3) million | $(19.8) million |
| Operating Expenses | $17.3 million | $21.6 million |
| Cash and Restricted Cash (Year End) | $5.2 million | $2.6 million |
| Accumulated Deficit | $(264.5) million | $(247.3) million |
| Net Cash Used in Operating Activities | $(10.6) million | $(12.6) million |
| Net Cash Provided by Financing Activities | $13.2 million | $11.0 million |
Note: The filing text does not provide specific margin data as the company has no revenue.
Material Changes vs. Prior Period
- Operating Loss Reduction: Net loss decreased by approximately 12% (from $19.8M to $17.3M) primarily due to the absence of merger-related expenses ($3.3M in 2024) and restructuring costs ($1.7M in 2024) incurred during the Peak Bio acquisition and subsequent workforce reduction.
- Research & Development (R&D): R&D expenses decreased by 60% ($4.2M) to $2.8M. This was driven by the suspension of the HSCT-TMA clinical program (AK901) and preclinical PAS-nomacopan program, offset by increased spending on ADC preclinical development ($1.3M vs $0.05M in 2024).
- Impairment Loss: The company recognized a $5.2 million impairment loss on the PHP-303 intangible asset due to the reprioritization of resources to the ADC platform and the inability to find a collaborative partner.
- Debt and Equity Activity: Significant financing activity occurred in 2025, including multiple private placements, registered direct offerings, and note exchanges. Approximately $4 million of August 2025 notes were exchanged for pre-funded warrants and note exchange warrants in December 2025.
Guidance, Outlook, and Risks
Outlook and Guidance
- Cash Runway: Management expects existing cash ($5.2M as of Dec 31, 2025) to fund operations only into April 2026. The company explicitly states there is "substantial doubt" regarding its ability to continue as a going concern without additional capital.
- Development Timeline: The company aims to advance AKTX-101 into clinical trials by the first quarter of 2027, pending successful IND-enabling activities and GMP manufacturing (initiated with WuXi Biologics/XDC in Dec 2025).
- Capital Needs: Substantial additional capital is required to fund operations, service obligations, and advance clinical development. The company is actively seeking equity/debt financing or strategic collaborations.
Material Risks and Contingencies
- Going Concern: Recurring losses, negative cash flows, and an accumulated deficit of $264.5 million raise substantial doubt about the company's ability to continue operations.
- Nasdaq Listing Compliance: The company received notice of non-compliance with Nasdaq's minimum bid price requirement ($1.00 per ADS). It has until May 25, 2026, to regain compliance or risk delisting. A subsequent ADS ratio change (1:80,000) was announced in March 2026 to address this.
- Internal Controls: The company identified material weaknesses in internal controls over financial reporting related to IT general controls, purchase-to-pay processes, and business combination accounting. Remediation efforts are underway but not yet fully effective.
- Development Risk: No clinical studies have been initiated for active pipeline assets. Success depends on preclinical data translating to humans and securing regulatory approval.
Investor Verification Checklist
- Cash Runway Validation: Verify the accuracy of the "April 2026" cash runway estimate given the high burn rate and recent financing costs.
- Financing Status: Confirm the status of any new financing rounds or strategic partnerships announced after the filing date to ensure the going concern risk is mitigated.
- Nasdaq Compliance: Monitor the effectiveness of the March 2026 ADS ratio change in restoring compliance with Nasdaq listing rules.
- Internal Control Remediation: Review future filings (10-Q) for updates on the remediation of material weaknesses in internal controls over financial reporting.
- AKTX-101 Progress: Track the timeline for IND-enabling studies and the initiation of the Phase 1 trial, as delays could further strain liquidity.